Novoron Bioscience is pioneering drug development targeting low-density lipoprotein receptors, canonically mischaracterized as merely scavenger proteins. Novoron's unique technology enables precise targeting at both whole-receptor and micro-domain levels. These breakthroughs offer new hope for treating a variety of diseases including our areas of focus, namely neurological damage and disease in the CNS (i.e., tauopathies - including Alzheimer's disease - multiple sclerosis, spinal cord injuries).